


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-17. (Canceled)

18. (Currently amended) A compound of the formula (II):



II

wherein:

X is selected from the group consisting of -CH(R_{9a})-alkylene- and -CH(R_{9a})-alkenylene-, wherein the alkylene and alkenylene are optionally interrupted by one or more -O- groups;

R₁ and R' are independently selected from the group consisting of:

hydrogen,

alkyl,

alkenyl,

aryl,

arylalkylenyl,

heteroaryl,

heteroarylalkylenyl,

heterocyclyl,


heterocyclylalkylenyl, and

alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or


heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:

hydroxyl,
 alkyl,
 haloalkyl,
 hydroxyalkyl,
 alkoxy,
 dialkylamino,
 $-S(O)_{0-2}$ -alkyl,
 $-S(O)_{0-2}$ -aryl,
 $-NH-S(O)_2$ -alkyl,
 $-NH-S(O)_2$ -aryl,
 haloalkoxy,
 halogen,
 nitrile,
 nitro,
 aryl,
 heteroaryl,
 heterocyclyl,
 aryloxy,
 arylalkyleneoxy,
 $-C(O)-O$ -alkyl,
 $-C(O)-N(R_8)_2$,
 $-N(R_8)-C(O)$ -alkyl,
 $-O-C(O)$ -alkyl, and
 $-C(O)$ -alkyl;

or R_1 and R' can join together to form a ring system selected from the group consisting of:



wherein the total number of atoms in the ring is 4 to 9, and



wherein the total number of atoms in the ring is 4 to 9;

R_A and R_B are each independently selected from the group consisting of:

hydrogen,
 halogen,
 alkyl,
 alkenyl,
 alkoxy,
 alkylthio, and
 $-N(R_9)_2$;

or when taken together, R_A and R_B form a fused aryl ring or heteroaryl ring containing one heteroatom selected from the group consisting of N and S, wherein the aryl or heteroaryl ring is unsubstituted or substituted by one or more R groups;


or when taken together, R_A and R_B form a fused 5 to 7 membered saturated ring, optionally containing one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups;

R is selected from the group consisting of:

halogen,
 hydroxyl,
 alkyl,
 alkenyl,
 haloalkyl,
 alkoxy,
 alkylthio, and
 $-N(R_9)_2$;

R_2 is selected from the group consisting of:


-hydrogen,
-alkyl, and
-alkoxyalkyl;



Z is a bond or -O-;

each R₄ is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxyl, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

each R₅ is independently selected from the group consisting of:



each R₆ is independently selected from the group consisting of =O and =S;

each R₇ is independently C₂₋₇ alkylene;

each R₈ is independently selected from the group consisting of hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkoxy-C₁₋₁₀ alkylenyl, and aryl-C₁₋₁₀ alkylenyl;

each R₉ is independently selected from the group consisting of hydrogen and alkyl;

R_{9a} is selected from the group consisting of hydrogen and alkyl which is optionally interrupted by one or more -O- groups;

each R_{10} is independently C_{3-8} alkylene;

R_c and R_d are independently selected from the group consisting of hydrogen, halogen, hydroxyl, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and $-N(R_9)_2$; or R_c and R_d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;

each R_{11} is independently C_{1-6} alkylene or C_{2-6} alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R_{12} is selected from the group consisting of a bond, C_{1-5} alkylene, and C_{2-5} alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

each A is independently selected from the group consisting of -O-, $-C(O)-$, $-CH_2-$, $-S(O)_{0-2}-$, and $-N(R_4)-$;

A' is selected from the group consisting of -O-, $-S(O)_{0-2}-$, $-N(-Q-R_4)-$, and $-CH_2-$;

each Q is independently selected from the group consisting of a bond, $-C(R_6)-$, $-C(R_6)-C(R_6)-$, $-S(O)_2-$, $-C(R_6)-N(R_8)-W-$, $-S(O)_2-N(R_8)-$, $-C(R_6)-O-$, and $-C(R_6)-N(OR_9)-$,

each V is independently selected from the group consisting of $-C(R_6)-$, $-O-C(R_6)-$, $-N(R_8)-C(R_6)-$, and $-S(O)_2-$;

each W is independently selected from the group consisting of a bond, $-C(O)-$, and $-(O)_2-$;

a and b are independently integers from 1 to 6 with the proviso that $a + b \leq 7$;

or a pharmaceutically acceptable salt thereof.


19. (Canceled)

20. (Previously presented) The compound or salt of claim 18 wherein X is $-C_{3-5}$ alkylene- or $-CH_2CH_2OCH_2CH_2-$.

21. (Previously presented) The compound or salt of claim 18 wherein at least one of R' or R_1 is hydrogen.

22. (Previously presented) The compound or salt of claim 18 wherein at least one of R' or R₁ is selected from the group consisting of aryl, heteroaryl, and alkyl, wherein the aryl, heteroaryl, and alkyl are optionally substituted.

23-25. (Canceled)

26. (Previously presented) The compound or salt of claim 18 wherein the ring system is , wherein Q is a bond or -C(O)-, and R₄ is alkyl.

27. (Previously presented) The compound or salt of claim 18 wherein R₁ and R' are each methyl.

28. (Canceled)

29. (Canceled)


30. (Currently amended) The compound or salt of claim ~~18~~ 29 wherein R₂ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, ethoxymethyl, methoxyethyl, and methoxymethyl.

31. (Canceled)

32. (Previously presented) The compound or salt of claim 18 wherein R_A and R_B form a fused aryl ring or heteroaryl ring containing one N, wherein the aryl ring or heteroaryl ring is unsubstituted.

33. (Canceled)

34. (Currently amended) A compound of the formula (III):



III

wherein:

X is selected from the group consisting of -CH(R_{9a})-alkylene- and -CH(R_{9a})-alkenylene-, wherein the alkylene and alkenylene are optionally interrupted by one or more -O- groups;

each R is independently selected from the group consisting of:

halogen,
hydroxyl,
alkyl,
alkenyl,
haloalkyl,
alkoxy,
alkylthio, and
-N(R₉)₂;


R₁ and R' are independently selected from the group consisting of:

hydrogen,
alkyl,
alkenyl,
aryl,
arylalkylenyl,
heteroaryl,
heteroarylalkylenyl,


heterocyclyl,
heterocyclylalkylenyl, and
alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or
heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:

hydroxyl,
haloalkyl,
hydroxyalkyl,
alkoxy,
dialkylamino,
-S(O)₀₋₂-alkyl,
-S(O)₀₋₂-aryl,
-NH-S(O)₂-alkyl,
-NH-S(O)₂-aryl,
haloalkoxy,
halogen,
nitrile,
nitro,
aryl,
heteroaryl,
heterocyclyl,
aryloxy,
arylalkyleneoxy,
-C(O)-O-alkyl,
-C(O)-N(R₈)₂,
-N(R₈)-C(O)-alkyl,
-O-C(O)-alkyl, and
-C(O)-alkyl;

or R₁ and R' can join together to form a ring system selected from the group consisting of:



wherein the total number of atoms in the ring is 4 to 9, and



wherein the total number of atoms in the ring is 4 to 9;

R₂ is selected from the group consisting of:

-hydrogen,

-alkyl, and

-alkoxyalkyl;

~~-R₄₅~~

~~-X'-R₄₅~~

~~-X'-Y-R₄₅, and~~

~~-X'-R₅₅~~

R₃ is selected from the group consisting of:

-Z-R₄,

-Z-X'-R₄,

-Z-X'-Y-R₄, and

-Z-X'-R₅;

each X' is independently selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene, wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene, heteroarylene, or heterocyclylene, and optionally interrupted by one or more -O- groups;

each Y is independently selected from the group consisting of:

-S(O)₀₋₂-,


-S(O)₂-N(R₈)-,

-C(R₆)-,

-C(R₆)-O-,

-O-C(R₆)-,


-O-C(O)-O-,



Z is a bond or -O-;

each R_4 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxyl, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

each R_5 is independently selected from the group consisting of:



each R₆ is independently selected from the group consisting of =O and =S;

each R₇ is independently C₂₋₇ alkylene;

each R₈ is independently selected from the group consisting of hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkoxy-C₁₋₁₀ alkyl, and aryl-C₁₋₁₀ alkyl;

each R₉ is independently selected from the group consisting of hydrogen and alkyl;

R_{9a} is selected from the group consisting of hydrogen and alkyl which is optionally interrupted by one or more -O- groups;

each R₁₀ is independently C₃₋₈ alkylene;

R_c and R_d are independently selected from the group consisting of hydrogen, halogen, hydroxyl, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N(R₉)₂; or R_c and R_d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;

each R₁₁ is independently C₁₋₆ alkylene or C₂₋₆ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

R₁₂ is selected from the group consisting of a bond, C₁₋₅ alkylene, and C₂₋₅ alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;

each A is independently selected from the group consisting of -O-, -C(O)-, -CH₂-, -S(O)₀₋₂-, and -N(R₄)-;

A' is selected from the group consisting of -O-, -S(O)₀₋₂-, -N(-Q-R₄)-, and -CH₂-;

each Q is independently selected from the group consisting of a bond, -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, and -C(R₆)-N(OR₉)-;

each V is independently selected from the group consisting of -C(R₆)-, -O-C(R₆)-, -N(R₈)-C(R₆)-, and -S(O)₂-;

each W is independently selected from the group consisting of a bond, -C(O)-, and -S(O)₂-;

a and b are independently integers from 1 to 6 with the proviso that a + b is ≤ 7;

n is an integer from 0 to 4;

and m is 0 or 1, with the proviso that when m is 1, n is 0 or 1;

or a pharmaceutically acceptable salt thereof.

35. (Canceled)


36. (Previously presented) The compound or salt of claim 34 wherein X is -C₃₋₅ alkylene- or -CH₂CH₂OCH₂CH₂-.

37. (Previously presented) The compound or salt of 34 wherein at least one of R' or R₁ is hydrogen.

38. (Previously presented) The compound or salt of claim 34 wherein at least one of R' or R₁ is selected from the group consisting of aryl, heteroaryl, and alkyl, wherein the aryl, heteroaryl, and alkyl are optionally substituted.

39-41. (Canceled)

42. (Previously presented) The compound or salt of claim 34 wherein the ring system is



43. (Previously presented) The compound or salt of claim 34 wherein R₁ and R' are each methyl.

44. (Canceled)

45. (Canceled)

46. (Currently amended) The compound or salt of claim 34 ~~45~~ wherein R₂ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, ethoxymethyl, 2-methoxyethyl,


and methoxymethyl.

47. (Canceled)

48. (Previously presented) The compound of salt of claim 34 wherein m and n are each 0.

49-62. (Canceled)

63. (Currently amended) A compound of the formula (V):



wherein:

X is selected from the group consisting of -CH(R_{9a})-alkylene- and -CH(R_{9a})-alkenylene-; R₁ and R' are independently selected from the group consisting of:

hydrogen,

alkyl,

alkenyl,

aryl,

alkylene-aryl,

heteroaryl,

heterocyclyl, and

alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl or heterocyclyl substituted by one or more substituents selected from the group consisting of:

hydroxyl,

alkyl,

haloalkyl,
hydroxyalkyl,
-O-alkyl,
-S-alkyl,
-O-haloalkyl,
halogen,
nitrile,
aryl,
heteroaryl,
heterocyclyl,
-O-aryl,
-O-alkylene-aryl,
-C(O)-O-alkyl,
-C(O)-N(R_{8a})₂, and -N(R_{8a})-C(O)-alkyl;

or R₁ and R' can join together to form a ring system containing one or two saturated or unsaturated rings optionally including one or more heteroatoms;

n is an integer from 0 to 4;

each R is independently selected from the group consisting of alkyl, alkoxy, halogen, hydroxyl, and trifluoromethyl;

R₂ is selected from the group consisting of:

hydrogen,
alkyl, and
alkoxyalkyl;
~~alkenyl~~,
~~aryl~~,
~~heteroaryl~~,
~~heterocyclyl~~,
~~alkylene-Y''-alkyl~~,
~~alkylene-Y''-alkenyl~~;

alkylene-Y''-aryl, and
~~alkyl or alkenyl substituted by one or more substituents selected from the group~~
 consisting of:

hydroxyl,
 halogen,
~~N(R_{8a})₂~~,
~~C(O)-C₁₋₁₀-alkyl~~,
~~C(O)-O-C₁₋₁₀-alkyl~~,
~~N₃~~,
 aryl,
 heteroaryl,
 heterocyclyl,
~~C(O)-aryl~~, and
~~C(O)-heteroaryl~~;


Y'' is -O- or -O-S(O)₀₋₂;

R_{9a} is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- groups; and

each R_{8a} is independently selected from the group consisting of hydrogen, C₁₋₁₀ alkyl, and C₂₋₁₀ alkenyl; or a pharmaceutically acceptable salt thereof.

64-93. (Canceled)

94. (Withdrawn and currently amended) A compound of the formula (VIII):



VIII

wherein:

X is selected from the group consisting of $-\text{CH}(\text{R}_{9a})$ -alkylene- and $-\text{CH}(\text{R}_{9a})$ -alkenylene-, wherein the alkylene and alkenylene are optionally interrupted by one or more -O- groups;

each R is independently selected from the group consisting of:

halogen,
hydroxyl,
alkyl,
alkenyl,
haloalkyl,
alkoxy,
alkylthio, and
 $-\text{N}(\text{R}_9)_2$;

R_1 and R' are independently selected from the group consisting of:


hydrogen,
alkyl,
alkenyl,
aryl,
arylalkylenyl,
heteroaryl,
heteroarylalkylenyl,
heterocyclyl,
heterocyclylalkylenyl, and

alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of:


hydroxyl,
haloalkyl,
hydroxyalkyl,
alkoxy,
dialkylamino,

-S(O)₀₋₂-alkyl,
 -S(O)₀₋₂-aryl,
 -NH-S(O)₂-alkyl,
 -NH-S(O)₂-aryl,
 haloalkoxy,
 halogen,
 nitrile,
 nitro,
 aryl,
 heteroaryl,
 heterocyclyl,
 aryloxy,
 arylalkyleneoxy,
 -C(O)-O-alkyl,
 -C(O)-N(R₈)₂,
 -N(R₈)-C(O)-alkyl,
 -O-C(O)-alkyl, and
 -C(O)-alkyl;

or R₁ and R' can join together to form a ring system selected from the group consisting of:




wherein the total number of atoms in the ring is 4 to 9, and





wherein the total number of atoms in the ring is 4 to 9;

R₂ is selected from the group consisting of:

-hydrogen,
-alkyl, and
-alkoxyalkyl;
~~-R₄₇~~












R₃ is selected from the group consisting of:



each X' is independently selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene, wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene, heteroarylene, or heterocyclylene, and optionally interrupted by one or more -O- groups;

each Y is independently selected from the group consisting of:



each R_9 is independently selected from the group consisting of hydrogen and alkyl;
 R_{9a} is selected from the group consisting of hydrogen and alkyl which is optionally interrupted by one or more -O- groups;
each R_{10} is independently C_{3-8} alkylene;
 R_c and R_d are independently selected from the group consisting of hydrogen, halogen, hydroxyl, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and $-N(R_9)_2$; or R_c and R_d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;
each R_{11} is independently C_{1-6} alkylene or C_{2-6} alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
 R_{12} is selected from the group consisting of a bond, C_{1-5} alkylene, and C_{2-5} alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
each A is independently selected from the group consisting of -O-, $-C(O)-$, $-CH_2-$, $-S(O)_{0-2}-$, and $-N(R_4)-$;
A' is selected from the group consisting of -O-, $-S(O)_{0-2}-$, $-N(-Q-R_4)-$, and $-XH_2-$;
each Q is independently selected from the group consisting of a bond, $-C(R_6)-$, $-C(R_6)-C(R_6)-$, $-S(O)_2-$, $-C(R_6)-N(R_8)-W-$, $-S(O)_2-N(R_8)-$, $-C(R_6)-O-$, and $-C(R_6)-N(OR_9)-$;
each V is independently selected from the group consisting of $-C(R_6)-$, $-O-C(R_6)-$, $-N(RP)-C(R)-$, and $-S(O)_2-$;
each W is independently selected from the group consisting of a bond, $-C(O)-$, and $-S(O)_2-$;
a and b are independently integers from 1 to 6 with the proviso that $a + b \leq 7$;
n is an integer from 0 to 3;
and m is 0 or 1, with the proviso that when m is 1, n is 0 or 1;
or a pharmaceutically acceptable salt thereof.

95. (Canceled)


96. (Withdrawn) The compound or salt of claim 94 wherein X is $-C_{3-5}$ alkylene- or $-CH_3CH_2OCH_2CH_2-$.

97. (Withdrawn) The compound or salt or claim 94 wherein at least one of R' or R₁ is hydrogen.


98. (Withdrawn) The compound or salt of claim 94 wherein at least one of R' or R₁ is selected from the group consisting of aryl, heteroaryl, and alkyl, wherein the aryl, heteroaryl, and alkyl are optionally substituted.

99-100. (Canceled)

101. (Withdrawn) The compound or salt of claim 94 wherein R₁ and R' join together to form a

ring system of the formula  wherein A' is -N(-Q-R₄)- or -CH₂-, Q is a bond or -C(O)-, and R₄ is alkyl.

102. (Withdrawn) The compound or salt or claim 101 wherein the ring system is



103. (Withdrawn) The compound or salt of claim 94 wherein R₁ and R' are each methyl.

104-105. (Canceled)

106. (Withdrawn and currently amended) The compound or salt of claim 94 ~~105~~ wherein R₂ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, ethoxymethyl, 2-methoxyethyl, and methoxymethyl.

107. (Canceled)

108. (Withdrawn) The compound or salt of claim 94 wherein m and n are each 0.

109-133. (Canceled)

134. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 18 in combination with a pharmaceutically acceptable carrier.

135. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 18 to the animal.

136. (Withdrawn) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 18 to the animal.

137. (Withdrawn) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 18 to the animal.

138. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 34 in combination with a pharmaceutically acceptable carrier.

139. (Withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 94 in combination with a pharmaceutically acceptable carrier.

140. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 34 to the animal.

141. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising

administering an effective amount of a compound or salt of claim 94 to the animal.

142. (Withdrawn) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 34 to the animal.

143. (Withdrawn) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 94 to the animal.

144. (Withdrawn) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 34 to the animal.

145. (Withdrawn) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 94 to the animal.